Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 340

1.

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response.

Martelli AM, Paganelli F, Fazio A, Bazzichetto C, Conciatori F, McCubrey JA.

Cancers (Basel). 2019 May 6;11(5). pii: E629. doi: 10.3390/cancers11050629. Review.

2.

Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.

Akula SM, Candido S, Libra M, Abrams SL, Steelman LS, Lertpiriyapong K, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lin HL, Lombardi P, McCubrey JA.

Adv Biol Regul. 2019 Apr 21. pii: S2212-4926(19)30029-6. doi: 10.1016/j.jbior.2019.04.003. [Epub ahead of print]

PMID:
31047842
3.

miRNAs and their roles in KSHV pathogenesis.

Hussein HAM, Alfhili MA, Pakala P, Simon S, Hussain J, McCubrey JA, Akula SM.

Virus Res. 2019 Jun;266:15-24. doi: 10.1016/j.virusres.2019.03.024. Epub 2019 Apr 2. Review.

PMID:
30951791
4.

Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.

Chiarini F, Evangelisti C, Lattanzi G, McCubrey JA, Martelli AM.

Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1322-1337. doi: 10.1016/j.bbamcr.2019.03.013. Epub 2019 Mar 27. Review.

PMID:
30928610
5.

Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.

Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-Silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin HL, Libra M, Akula SM, McCubrey JA.

Adv Biol Regul. 2019 May;72:22-40. doi: 10.1016/j.jbior.2019.03.002. Epub 2019 Mar 15.

PMID:
30898612
6.

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

Follo MY, Pellagatti A, Armstrong RN, Ratti S, Mongiorgi S, De Fanti S, Bochicchio MT, Russo D, Gobbi M, Miglino M, Parisi S, Martinelli G, Cavo M, Luiselli D, McCubrey JA, Suh PG, Manzoli L, Boultwood J, Finelli C, Cocco L.

Leukemia. 2019 Feb 20. doi: 10.1038/s41375-019-0416-x. [Epub ahead of print]

PMID:
30787430
7.

Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.

Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovì S, Puleio R, Cassata G, Gulino A, Belmonte B, Gramignoli R, Strom SC, McCubrey JA, Montalto G, Cervello M.

Int J Cancer. 2019 May 15;144(10):2613-2624. doi: 10.1002/ijc.31963. Epub 2018 Dec 24.

PMID:
30488605
8.

Nuclear Nox4 interaction with prelamin A is associated with nuclear redox control of stem cell aging.

Casciaro F, Beretti F, Zavatti M, McCubrey JA, Ratti S, Marmiroli S, Follo MY, Maraldi T.

Aging (Albany NY). 2018 Oct 24;10(10):2911-2934. doi: 10.18632/aging.101599.

9.

Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.

Abrams SL, Follo MY, Steelman LS, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lombardi P, McCubrey JA.

Adv Biol Regul. 2019 Jan;71:172-182. doi: 10.1016/j.jbior.2018.10.003. Epub 2018 Oct 17.

PMID:
30361003
10.

Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders.

Ratti S, Follo MY, Ramazzotti G, Faenza I, Fiume R, Suh PG, McCubrey JA, Manzoli L, Cocco L.

J Lipid Res. 2019 Feb;60(2):312-317. doi: 10.1194/jlr.R089763. Epub 2018 Oct 4.

PMID:
30287524
11.

Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging.

Duda P, Wiśniewski J, Wójtowicz T, Wójcicka O, Jaśkiewicz M, Drulis-Fajdasz D, Rakus D, McCubrey JA, Gizak A.

Expert Opin Ther Targets. 2018 Oct;22(10):833-848. doi: 10.1080/14728222.2018.1526925. Epub 2018 Sep 26. Review.

PMID:
30244615
12.

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.

Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:16-34. doi: 10.1016/j.jbior.2018.06.002. Epub 2018 Jun 28.

PMID:
29980405
13.

Systematic analysis of GSK-3 signaling pathways in aging of cerebral tissue.

Drulis-Fajdasz D, Rakus D, Wiśniewski JR, McCubrey JA, Gizak A.

Adv Biol Regul. 2018 Aug;69:35-42. doi: 10.1016/j.jbior.2018.06.001. Epub 2018 Jun 21.

PMID:
29958836
14.

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.

Evangelisti C, Chiarini F, McCubrey JA, Martelli AM.

Int J Mol Sci. 2018 Jun 26;19(7). pii: E1878. doi: 10.3390/ijms19071878. Review.

15.

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines.

Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:43-62. doi: 10.1016/j.jbior.2018.05.002. Epub 2018 May 18.

PMID:
29861174
16.

Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise.

Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17238-17254. doi: 10.18632/oncotarget.24428. eCollection 2018 Mar 30. Review.

17.

Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases.

Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17220-17237. doi: 10.18632/oncotarget.24991. eCollection 2018 Mar 30. Review.

18.

Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.

Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, Neri LM.

J Cell Physiol. 2018 Oct;233(10):6440-6454. doi: 10.1002/jcp.26539. Epub 2018 Apr 18. Review.

PMID:
29667769
19.

Impact of physical exercise in cancer survivors during and after antineoplastic treatments.

Ferioli M, Zauli G, Martelli AM, Vitale M, McCubrey JA, Ultimo S, Capitani S, Neri LM.

Oncotarget. 2018 Feb 8;9(17):14005-14034. doi: 10.18632/oncotarget.24456. eCollection 2018 Mar 2. Review.

20.

Cutaneous melanoma: From pathogenesis to therapy (Review).

Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Candido S, Libra M.

Int J Oncol. 2018 Apr;52(4):1071-1080. doi: 10.3892/ijo.2018.4287. Epub 2018 Feb 27. Review.

21.

Drug discovery targeting the mTOR pathway.

Martelli AM, Buontempo F, McCubrey JA.

Clin Sci (Lond). 2018 Mar 9;132(5):543-568. doi: 10.1042/CS20171158. Print 2018 Mar 15. Review.

PMID:
29523752
22.

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis.

Mammana S, Bramanti P, Mazzon E, Cavalli E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F, Mangano K.

Oncotarget. 2018 Jan 3;9(9):8263-8277. doi: 10.18632/oncotarget.23862. eCollection 2018 Feb 2.

23.

Metformin influences drug sensitivity in pancreatic cancer cells.

Candido S, Abrams SL, Steelman L, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Suh PG, Libra M, McCubrey JA.

Adv Biol Regul. 2018 May;68:13-30. doi: 10.1016/j.jbior.2018.02.002. Epub 2018 Feb 12.

PMID:
29482945
24.

Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell.

Wiśniewski J, Piróg M, Hołubowicz R, Dobryszycki P, McCubrey JA, Rakus D, Gizak A.

Oncotarget. 2017 Dec 15;8(70):115420-115433. doi: 10.18632/oncotarget.23271. eCollection 2017 Dec 29.

25.

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.

Steelman LS, Abrams SL, Ruvolo P, Ruvolo V, Cocco L, Ratti S, Martelli AM, Neri LM, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Dec 6;8(68):113013-113033. doi: 10.18632/oncotarget.22956. eCollection 2017 Dec 22.

26.

Neuron-derived transthyretin modulates astrocytic glycolysis in hormone-independent manner.

Zawiślak A, Jakimowicz P, McCubrey JA, Rakus D.

Oncotarget. 2017 Nov 20;8(63):106625-106638. doi: 10.18632/oncotarget.22542. eCollection 2017 Dec 5.

27.

Bevacizumab in the treatment of NSCLC: patient selection and perspectives.

Russo AE, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferraù F.

Lung Cancer (Auckl). 2017 Dec 14;8:259-269. doi: 10.2147/LCTT.S110306. eCollection 2017. Review.

28.

Nuclear inositide signaling and cell cycle.

Ratti S, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Billi AM, McCubrey JA, Suh PG, Manzoli L, Cocco L, Follo MY.

Adv Biol Regul. 2018 Jan;67:1-6. doi: 10.1016/j.jbior.2017.10.008. Epub 2017 Oct 23. Review.

PMID:
29102395
29.

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Aug 24;8(44):76525-76557. doi: 10.18632/oncotarget.20408. eCollection 2017 Sep 29.

30.

Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals.

McCubrey JA, Abrams SL, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS.

Adv Biol Regul. 2018 Jan;67:190-211. doi: 10.1016/j.jbior.2017.09.012. Epub 2017 Oct 3.

PMID:
28988970
31.

Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).

Poli A, Ratti S, Finelli C, Mongiorgi S, Clissa C, Lonetti A, Cappellini A, Catozzi A, Barraco M, Suh PG, Manzoli L, McCubrey JA, Cocco L, Follo MY.

FASEB J. 2018 Feb;32(2):681-692. doi: 10.1096/fj.201700690R. Epub 2018 Jan 4.

PMID:
28970249
32.

Therapeutic targeting of CK2 in acute and chronic leukemias.

Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM.

Leukemia. 2018 Jan;32(1):1-10. doi: 10.1038/leu.2017.301. Epub 2017 Sep 27. Review.

33.

GSK-3 signaling in health.

McCubrey JA, Cocco L.

Adv Biol Regul. 2017 Aug;65:1-4. doi: 10.1016/j.jbior.2017.06.004. Epub 2017 Jul 1. No abstract available.

PMID:
28705437
34.

Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation.

Cusimano A, Balasus D, Azzolina A, Augello G, Emma MR, Di Sano C, Gramignoli R, Strom SC, McCubrey JA, Montalto G, Cervello M.

Int J Oncol. 2017 Aug;51(2):533-544. doi: 10.3892/ijo.2017.4049. Epub 2017 Jun 21.

PMID:
28656311
35.

Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma.

Cervello M, Augello G, Cusimano A, Emma MR, Balasus D, Azzolina A, McCubrey JA, Montalto G.

Adv Biol Regul. 2017 Aug;65:59-76. doi: 10.1016/j.jbior.2017.06.002. Epub 2017 Jun 6. Review.

PMID:
28619606
36.

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.

McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM, Cocco L, Ratti S, Martelli AM, Laidler P, Dulińska-Litewka J, Rakus D, Gizak A, Lombardi P, Nicoletti F, Candido S, Libra M, Montalto G, Cervello M.

Aging (Albany NY). 2017 Jun 12;9(6):1477-1536. doi: 10.18632/aging.101250. Review.

37.

Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases.

McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D.

Adv Biol Regul. 2017 Aug;65:77-88. doi: 10.1016/j.jbior.2017.05.005. Epub 2017 May 26. Review.

PMID:
28579298
38.

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.

Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.

39.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

40.

Nuclear Inositide Signaling Via Phospholipase C.

Ratti S, Mongiorgi S, Ramazzotti G, Follo MY, Mariani GA, Suh PG, McCubrey JA, Cocco L, Manzoli L.

J Cell Biochem. 2017 Aug;118(8):1969-1978. doi: 10.1002/jcb.25894. Epub 2017 Apr 25. Review.

PMID:
28106288
41.

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.

McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, Martelli AM, Laidler P, Dulińska-Litewka J, Rakus D, Gizak A, Nicoletti F, Falzone L, Candido S, Libra M.

Oncotarget. 2017 Feb 21;8(8):14221-14250. doi: 10.18632/oncotarget.13991. Review.

42.

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.

Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2016 Nov 29;7(48):79842-79853. doi: 10.18632/oncotarget.13035.

43.

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.

McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM.

Biochim Biophys Acta. 2016 Dec;1863(12):2942-2976. doi: 10.1016/j.bbamcr.2016.09.004. Epub 2016 Sep 6. Review.

44.

PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis.

Ramazzotti G, Faenza I, Fiume R, Billi AM, Manzoli L, Mongiorgi S, Ratti S, McCubrey JA, Suh PG, Cocco L, Follo MY.

Adv Biol Regul. 2017 Jan;63:1-5. doi: 10.1016/j.jbior.2016.10.005. Epub 2016 Oct 18. Review.

PMID:
27776973
45.

Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.

McCubrey JA, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Rakus D, Gizak A, Libra M, Cervello M, Montalto G, Yang LV, Abrams SL, Steelman LS.

Adv Biol Regul. 2017 Jan;63:32-48. doi: 10.1016/j.jbior.2016.10.001. Epub 2016 Oct 6. Review.

PMID:
27776972
46.

Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.

Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M, Libra M.

Oncotarget. 2016 Nov 8;7(45):72758-72766. doi: 10.18632/oncotarget.11805.

47.

Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.

Alameen AA, Simioni C, Martelli AM, Zauli G, Ultimo S, McCubrey JA, Gonelli A, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2016 Aug 23;7(34):55690-55703. doi: 10.18632/oncotarget.10984.

48.

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.

Emma MR, Iovanna JL, Bachvarov D, Puleio R, Loria GR, Augello G, Candido S, Libra M, Gulino A, Cancila V, McCubrey JA, Montalto G, Cervello M.

Cell Death Dis. 2016 Jun 23;7(6):e2269. doi: 10.1038/cddis.2016.175.

49.

MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma.

Falzone L, Salemi R, Travali S, Scalisi A, McCubrey JA, Candido S, Libra M.

Aging (Albany NY). 2016 May;8(5):933-44. doi: 10.18632/aging.100951.

50.

The therapeutic potential of mTOR inhibitors in breast cancer.

Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA.

Br J Clin Pharmacol. 2016 Nov;82(5):1189-1212. doi: 10.1111/bcp.12958. Epub 2016 May 10. Review.

Supplemental Content

Loading ...
Support Center